Abstract

Angiosarcoma is a rare and aggressive malignant neoplasm of unknown etiology, representing only 1% of all sarcomas, with half occurring in the head and neck region.1 It is a subtype of vascular sarcoma, and usually affects patients in the sixth or seventh decade of life. Treatment includes resection with wide margins, with postoperative scalp radiation therapy frequently recommended, given the local failure rate of approximately 50%. Increasingly, systemic or targeted agents are utilized with the aim of improving the 5-year survival rate, which is usually less than 20%.2 Metastatic disease is common, and usually involves lungs and liver. In the head and neck, surgery can be difficult because of the infiltrating nature of the disease and the anatomic constraints of the head and neck that make wide surgical margins difficult to achieve. In such cases, definitive radiation therapy with (neoadjuvant or concurrent) chemotherapy is commonly utilized. Conventionally, total scalp irradiation is delivered using megavoltage photons and electrons, usually 6 MV

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.